Hemostemix Inc (TSE:HEM)
:HEM
Want to see TSE:HEM full AI Analyst Report?
HEM Stock Chart & Stats
C$0.08
C$0.03(23.81%)
At close: 4:00 PM EST
C$0.08
C$0.03(23.81%)
Day’s Range― - ―
52-Week RangeC$0.06 - C$0.16
Previous CloseN/A
Volume356.00K
Average Volume (3M)138.35K
Market Cap
C$11.87M
Enterprise ValueC$14.79M
Total Cash (Recent Filing)C$741.72K
Total Debt (Recent Filing)C$3.60M
Price to Earnings (P/E)―
Beta0.53
Next Earnings
May 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding197,796,450
10 Day Avg. Volume155,944
30 Day Avg. Volume138,348
Financial Highlights & Ratios
PEG Ratio-0.66
Price to Book (P/B)-2.96
Price to Sales (P/S)0.00
P/FCF Ratio-3.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical-stage Autologous Cell Therapy PlatformHemostemix’s positioning as a clinical-stage developer of autologous, patient-derived cell therapies targets large unmet needs in cardiovascular and ischemic disease. Clinical-stage progress reduces early scientific risk and positions the company for milestone-driven de‑risking and potential commercialization partnerships over months.
Declining Total Debt (2024→2025)A reduction in nominal debt from 2024 to 2025 indicates modest improvement in capital structure and slightly lower fixed financing obligations. This trend, if sustained, can improve flexibility and reduce interest burden, helping extend runway prior to the next financing or value‑creating milestone.
Cash Flow Aligns With Reported LossesFree cash flow closely matching net income suggests transparent accounting and predictable cash burn patterns. Reliable alignment between accrual results and cash impacts enables more accurate runway modelling and financing plans, aiding durable operational planning despite negative absolute cash flows.
Bears Say
No Revenue Across 2020–2025Absence of revenue over multiple years means the business lacks product commercialization and recurring cash inflows, leaving value dependent on clinical success or external financing. Persistent operating losses consume capital and maintain dependence on dilutive funding absent decisive clinical or partnership progress.
Chronic Negative Shareholders' EquitySustained negative equity reflects accumulated deficits and a weak capital base, constraining the company’s ability to absorb setbacks or fund scale-up. This structural weakness raises solvency concerns, reduces access to non‑dilutive financing, and increases the probability of dilutive capital raises.
Worsening Operating Cash Burn In 2025A sharp increase in operating cash outflows in 2025 materially shortens runway and intensifies near‑term financing needs. Elevated cash burn reduces strategic flexibility, forces financing under potentially unfavorable terms, and amplifies dilution and solvency risk over the coming months absent revenue or partnership inflection.
Hemostemix News
HEM FAQ
What was Hemostemix Inc’s price range in the past 12 months?
Hemostemix Inc lowest stock price was C$0.06 and its highest was C$0.16 in the past 12 months.
What is Hemostemix Inc’s market cap?
Hemostemix Inc’s market cap is C$11.87M.
When is Hemostemix Inc’s upcoming earnings report date?
Hemostemix Inc’s upcoming earnings report date is May 28, 2026 which is in 8 days.
How were Hemostemix Inc’s earnings last quarter?
Currently, no data Available
Is Hemostemix Inc overvalued?
According to Wall Street analysts Hemostemix Inc’s price is currently Overvalued.
Does Hemostemix Inc pay dividends?
Hemostemix Inc does not currently pay dividends.
What is Hemostemix Inc’s EPS estimate?
Hemostemix Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hemostemix Inc have?
Hemostemix Inc has 197,796,450 shares outstanding.
What happened to Hemostemix Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Hemostemix Inc?
Currently, no hedge funds are holding shares in TSE:HEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hemostemix Inc
Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of critical limb ischemia in Canada and the United States, as well as for the treatment of heart and peripheral arterial diseases. The company is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.
Technical Analysis
Options Prices
Currently, No data available
---